BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 29222231)

  • 1. AL amyloidosis: from molecular mechanisms to targeted therapies.
    Merlini G
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):1-12. PubMed ID: 29222231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New concepts in the treatment and diagnosis of amyloidosis.
    Milani P; Palladini G; Merlini G
    Expert Rev Hematol; 2018 Feb; 11(2):117-127. PubMed ID: 29307226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of the elderly patient with AL amyloidosis.
    Nuvolone M; Milani P; Palladini G; Merlini G
    Eur J Intern Med; 2018 Dec; 58():48-56. PubMed ID: 29801808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics.
    Rognoni P; Mazzini G; Caminito S; Palladini G; Lavatelli F
    Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
    Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
    Elife; 2020 Mar; 9():. PubMed ID: 32151314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside.
    Basset M; Nuvolone M; Palladini G; Merlini G
    Expert Rev Hematol; 2020 Sep; 13(9):1003-1015. PubMed ID: 32721177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
    Bhutani D; Leng S; Lentzsch S
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonchemotherapy Treatment of Immunoglobulin Light Chain Amyloidosis.
    Van Doren L; Lentzsch S
    Acta Haematol; 2020; 143(4):373-380. PubMed ID: 32526750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of AL amyloidosis in 2020.
    Palladini G; Milani P; Merlini G
    Blood; 2020 Dec; 136(23):2620-2627. PubMed ID: 33270858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
    Badar T; D'Souza A; Hari P
    F1000Res; 2018; 7():. PubMed ID: 30228867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How I treat AL amyloidosis.
    Palladini G; Merlini G
    Blood; 2022 May; 139(19):2918-2930. PubMed ID: 34517412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized Approach to Management of Light Chain Amyloidosis.
    Palladini G; Milani P
    J Natl Compr Canc Netw; 2023 Jan; 21(1):91-98. PubMed ID: 36634608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.
    Barrett CD; Dobos K; Liedtke M; Tuzovic M; Haddad F; Kobayashi Y; Lafayette R; Fowler MB; Arai S; Schrier S; Witteles RM
    JACC Heart Fail; 2019 Nov; 7(11):958-966. PubMed ID: 31606365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.
    Ikura H; Endo J; Kitakata H; Moriyama H; Sano M; Fukuda K
    Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin Light Chain Systemic Amyloidosis.
    Dispenzieri A; Merlini G
    Cancer Treat Res; 2016; 169():273-318. PubMed ID: 27696268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapies for cardiac light chain amyloidosis: An update.
    Aimo A; Buda G; Fontana M; Barison A; Vergaro G; Emdin M; Merlini G
    Int J Cardiol; 2018 Nov; 271():152-160. PubMed ID: 30223349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of AL amyloidosis in 2020.
    Palladini G; Milani P; Merlini G
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the management of AL Amyloidosis.
    Kastritis E; Dimopoulos MA
    Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic immunoglobulin light chain amyloidosis.
    Merlini G; Dispenzieri A; Sanchorawala V; Schönland SO; Palladini G; Hawkins PN; Gertz MA
    Nat Rev Dis Primers; 2018 Oct; 4(1):38. PubMed ID: 30361521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.